128 related articles for article (PubMed ID: 15840411)
1. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice.
Steioff K; Rütten H; Busch AE; Plettenburg O; Ivashchenko Y; Löhn M
Eur J Pharmacol; 2005 Apr; 512(2-3):247-9. PubMed ID: 15840411
[TBL] [Abstract][Full Text] [Related]
2. Effect of fasudil on macrovascular disorder-induced endothelial dysfunction.
Shah DI; Singh M
Can J Physiol Pharmacol; 2006; 84(8-9):835-45. PubMed ID: 17111028
[TBL] [Abstract][Full Text] [Related]
3. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.
Nohria A; Grunert ME; Rikitake Y; Noma K; Prsic A; Ganz P; Liao JK; Creager MA
Circ Res; 2006 Dec; 99(12):1426-32. PubMed ID: 17095725
[TBL] [Abstract][Full Text] [Related]
4. Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter.
Levent A; Büyükafsar K
Br J Pharmacol; 2004 Oct; 143(3):431-7. PubMed ID: 15351780
[TBL] [Abstract][Full Text] [Related]
5. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Abe K; Tawara S; Oi K; Hizume T; Uwatoku T; Fukumoto Y; Kaibuchi K; Shimokawa H
J Cardiovasc Pharmacol; 2006 Dec; 48(6):280-5. PubMed ID: 17204906
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Rho-kinase in experimental vascular endothelial dysfunction.
Shah DI; Singh M
Mol Cell Biochem; 2006 Feb; 283(1-2):191-9. PubMed ID: 16444602
[TBL] [Abstract][Full Text] [Related]
7. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.
Higashi M; Shimokawa H; Hattori T; Hiroki J; Mukai Y; Morikawa K; Ichiki T; Takahashi S; Takeshita A
Circ Res; 2003 Oct; 93(8):767-75. PubMed ID: 14500337
[TBL] [Abstract][Full Text] [Related]
8. Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model.
Park K; Kim SW; Rhu KS; Paick JS
J Sex Med; 2006 Nov; 3(6):996-1003. PubMed ID: 17100932
[TBL] [Abstract][Full Text] [Related]
9. Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms.
Shin HK; Salomone S; Potts EM; Lee SW; Millican E; Noma K; Huang PL; Boas DA; Liao JK; Moskowitz MA; Ayata C
J Cereb Blood Flow Metab; 2007 May; 27(5):998-1009. PubMed ID: 17033691
[TBL] [Abstract][Full Text] [Related]
10. Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats.
Tsounapi P; Saito M; Kitatani K; Dimitriadis F; Ohmasa F; Shimizu S; Kinoshita Y; Takenaka A; Satoh K
Eur J Pharmacol; 2012 Sep; 691(1-3):182-9. PubMed ID: 22819709
[TBL] [Abstract][Full Text] [Related]
11. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis.
Wang YX; Martin-McNulty B; da Cunha V; Vincelette J; Lu X; Feng Q; Halks-Miller M; Mahmoudi M; Schroeder M; Subramanyam B; Tseng JL; Deng GD; Schirm S; Johns A; Kauser K; Dole WP; Light DR
Circulation; 2005 May; 111(17):2219-26. PubMed ID: 15851596
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats.
Nishikimi T; Koshikawa S; Ishikawa Y; Akimoto K; Inaba C; Ishimura K; Ono H; Matsuoka H
J Hypertens; 2007 May; 25(5):1053-63. PubMed ID: 17414670
[TBL] [Abstract][Full Text] [Related]
13. Smoking, endothelial function, and Rho-kinase in humans.
Noma K; Goto C; Nishioka K; Hara K; Kimura M; Umemura T; Jitsuiki D; Nakagawa K; Oshima T; Chayama K; Yoshizumi M; Higashi Y
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2630-5. PubMed ID: 16210569
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.
Wang YX; da Cunha V; Martin-McNulty B; Vincelette J; Li W; Choy DF; Halks-Miller M; Mahmoudi M; Schroeder M; Johns A; Light DR; Dole WP
Eur J Pharmacol; 2005 Apr; 512(2-3):215-22. PubMed ID: 15840407
[TBL] [Abstract][Full Text] [Related]
15. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats.
Ishikawa Y; Nishikimi T; Akimoto K; Ishimura K; Ono H; Matsuoka H
Hypertension; 2006 Jun; 47(6):1075-83. PubMed ID: 16636194
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Abe K; Shimokawa H; Morikawa K; Uwatoku T; Oi K; Matsumoto Y; Hattori T; Nakashima Y; Kaibuchi K; Sueishi K; Takeshit A
Circ Res; 2004 Feb; 94(3):385-93. PubMed ID: 14670839
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury.
Thorlacius K; Slotta JE; Laschke MW; Wang Y; Menger MD; Jeppsson B; Thorlacius H
J Leukoc Biol; 2006 May; 79(5):923-31. PubMed ID: 16641138
[TBL] [Abstract][Full Text] [Related]
18. Rho-kinase inhibitor and nicotinamide adenine dinucleotide phosphate oxidase inhibitor prevent impairment of endothelium-dependent cerebral vasodilation by acute cigarette smoking in rats.
Iida H; Iida M; Takenaka M; Fukuoka N; Dohi S
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):89-94. PubMed ID: 18584584
[TBL] [Abstract][Full Text] [Related]
19. Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta.
Chan CK; Mak JC; Man RY; Vanhoutte PM
J Pharmacol Exp Ther; 2009 May; 329(2):820-6. PubMed ID: 19193928
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of Rho-kinase inhibition on artery wall mass and remodeling.
Pearce JD; Li J; Edwards MS; English WP; Geary RL
J Vasc Surg; 2004 Jan; 39(1):223-8. PubMed ID: 14718843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
